Jiangsu wuzhong(SH:600200) Zheng Quan Zhi Xing·2025-07-13 16:09Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. faces the risk of being delisted due to major illegal activities, as the China Securities Regulatory Commission (CSRC) has initiated an investigation into the company for suspected violations of information disclosure laws [1][3]. Group 1: Investigation and Allegations - The company received a notice from the CSRC on February 26, 2025, indicating that it is under investigation for engaging in trade activities with related companies that lacked commercial substance, resulting in inflated revenue, costs, and profits [1][3]. - The inflated figures from 2020 to 2023 include a revenue increase of 26.46%, 26.39%, 21.26%, and 16.82% for each respective year, with inflated costs amounting to 480.68 million, 448.24 million, 410.82 million, and 355.44 million yuan, representing 37.08%, 35.47%, 28.40%, and 20.95% of the reported costs [1][3]. Group 2: Potential Consequences - If the formal administrative penalty confirms that the company has engaged in major illegal activities, its stock will be terminated from listing [2][3]. - The company will apply for a trading suspension and disclose relevant information promptly if it receives an administrative penalty decision indicating that it has triggered the conditions for major illegal delisting [2][3]. Group 3: Compliance and Future Actions - The company commits to fully cooperating with the CSRC and will exercise its rights to hearings or statements to protect the interests of the company and its investors [3]. - Investors are advised to pay attention to subsequent announcements regarding the investigation and potential risks associated with their investments [2][3].